Rationale for Combination Therapy in Multiple Myeloma

Ajai Chari, MD, discusses the rationale for using combination therapy in patients with multiple myeloma. 

Ajai Chari, MD, associate professor of medicine at the Mount Sinai School of Medicine, discusses the rationale for using combination therapy in patients with multiple myeloma.

Historically, Chari says that every drug in the treatment landscape has only worked for a short period of time in these patients. Because of this, the agents are combined to increase both response and duration of response, while also decreasing resistance.